Biopharmaceuticals-EMEA Market Status and Trend Report 2013-2023
Report Summary
Biopharmaceuticals-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biopharmaceuticals industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biopharmaceuticals 2013-2017, and development forecast 2018-2023
Main market players of Biopharmaceuticals in EMEA, with company and product introduction, position in the Biopharmaceuticals market
Market status and development trend of Biopharmaceuticals by types and applications
Cost and profit status of Biopharmaceuticals, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biopharmaceuticals market as:
EMEA Biopharmaceuticals Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biopharmaceuticals Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Monoclonal Antibodies
Interferon
Colony-Stimulating Factor
Erythropoietin
Insulin
Vaccines
Growth Hormones
Other
EMEA Biopharmaceuticals Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
EMEA Biopharmaceuticals Market: Players Segment Analysis (Company and Product introduction, Biopharmaceuticals Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biopharmaceuticals-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biopharmaceuticals industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biopharmaceuticals 2013-2017, and development forecast 2018-2023
Main market players of Biopharmaceuticals in EMEA, with company and product introduction, position in the Biopharmaceuticals market
Market status and development trend of Biopharmaceuticals by types and applications
Cost and profit status of Biopharmaceuticals, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biopharmaceuticals market as:
EMEA Biopharmaceuticals Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biopharmaceuticals Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Monoclonal Antibodies
Interferon
Colony-Stimulating Factor
Erythropoietin
Insulin
Vaccines
Growth Hormones
Other
EMEA Biopharmaceuticals Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
EMEA Biopharmaceuticals Market: Players Segment Analysis (Company and Product introduction, Biopharmaceuticals Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOPHARMACEUTICALS
1.1 Definition of Biopharmaceuticals in This Report
1.2 Commercial Types of Biopharmaceuticals
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Colony-Stimulating Factor
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Growth Hormones
1.2.8 Other
1.3 Downstream Application of Biopharmaceuticals
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biopharmaceuticals
1.5 Market Status and Trend of Biopharmaceuticals 2013-2023
1.5.1 EMEA Biopharmaceuticals Market Status and Trend 2013-2023
1.5.2 Regional Biopharmaceuticals Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biopharmaceuticals in EMEA 2013-2017
2.2 Consumption Market of Biopharmaceuticals in EMEA by Regions
2.2.1 Consumption Volume of Biopharmaceuticals in EMEA by Regions
2.2.2 Revenue of Biopharmaceuticals in EMEA by Regions
2.3 Market Analysis of Biopharmaceuticals in EMEA by Regions
2.3.1 Market Analysis of Biopharmaceuticals in Europe 2013-2017
2.3.2 Market Analysis of Biopharmaceuticals in Middle East 2013-2017
2.3.3 Market Analysis of Biopharmaceuticals in Africa 2013-2017
2.4 Market Development Forecast of Biopharmaceuticals in EMEA 2018-2023
2.4.1 Market Development Forecast of Biopharmaceuticals in EMEA 2018-2023
2.4.2 Market Development Forecast of Biopharmaceuticals by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biopharmaceuticals in EMEA by Types
3.1.2 Revenue of Biopharmaceuticals in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biopharmaceuticals in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biopharmaceuticals in EMEA by Downstream Industry
4.2 Demand Volume of Biopharmaceuticals by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biopharmaceuticals by Downstream Industry in Europe
4.2.2 Demand Volume of Biopharmaceuticals by Downstream Industry in Middle East
4.2.3 Demand Volume of Biopharmaceuticals by Downstream Industry in Africa
4.3 Market Forecast of Biopharmaceuticals in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOPHARMACEUTICALS
5.1 EMEA Economy Situation and Trend Overview
5.2 Biopharmaceuticals Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOPHARMACEUTICALS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biopharmaceuticals in EMEA by Major Players
6.2 Revenue of Biopharmaceuticals in EMEA by Major Players
6.3 Basic Information of Biopharmaceuticals by Major Players
6.3.1 Headquarters Location and Established Time of Biopharmaceuticals Major Players
6.3.2 Employees and Revenue Level of Biopharmaceuticals Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOPHARMACEUTICALS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biopharmaceuticals Product
7.1.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biopharmaceuticals Product
7.2.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biopharmaceuticals Product
7.3.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biopharmaceuticals Product
7.4.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biopharmaceuticals Product
7.5.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biopharmaceuticals Product
7.6.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biopharmaceuticals Product
7.7.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biopharmaceuticals Product
7.8.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biopharmaceuticals Product
7.9.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biopharmaceuticals Product
7.10.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Merck
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOPHARMACEUTICALS
8.1 Industry Chain of Biopharmaceuticals
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOPHARMACEUTICALS
9.1 Cost Structure Analysis of Biopharmaceuticals
9.2 Raw Materials Cost Analysis of Biopharmaceuticals
9.3 Labor Cost Analysis of Biopharmaceuticals
9.4 Manufacturing Expenses Analysis of Biopharmaceuticals
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOPHARMACEUTICALS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Biopharmaceuticals in This Report
1.2 Commercial Types of Biopharmaceuticals
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Colony-Stimulating Factor
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Growth Hormones
1.2.8 Other
1.3 Downstream Application of Biopharmaceuticals
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biopharmaceuticals
1.5 Market Status and Trend of Biopharmaceuticals 2013-2023
1.5.1 EMEA Biopharmaceuticals Market Status and Trend 2013-2023
1.5.2 Regional Biopharmaceuticals Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biopharmaceuticals in EMEA 2013-2017
2.2 Consumption Market of Biopharmaceuticals in EMEA by Regions
2.2.1 Consumption Volume of Biopharmaceuticals in EMEA by Regions
2.2.2 Revenue of Biopharmaceuticals in EMEA by Regions
2.3 Market Analysis of Biopharmaceuticals in EMEA by Regions
2.3.1 Market Analysis of Biopharmaceuticals in Europe 2013-2017
2.3.2 Market Analysis of Biopharmaceuticals in Middle East 2013-2017
2.3.3 Market Analysis of Biopharmaceuticals in Africa 2013-2017
2.4 Market Development Forecast of Biopharmaceuticals in EMEA 2018-2023
2.4.1 Market Development Forecast of Biopharmaceuticals in EMEA 2018-2023
2.4.2 Market Development Forecast of Biopharmaceuticals by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biopharmaceuticals in EMEA by Types
3.1.2 Revenue of Biopharmaceuticals in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biopharmaceuticals in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biopharmaceuticals in EMEA by Downstream Industry
4.2 Demand Volume of Biopharmaceuticals by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biopharmaceuticals by Downstream Industry in Europe
4.2.2 Demand Volume of Biopharmaceuticals by Downstream Industry in Middle East
4.2.3 Demand Volume of Biopharmaceuticals by Downstream Industry in Africa
4.3 Market Forecast of Biopharmaceuticals in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOPHARMACEUTICALS
5.1 EMEA Economy Situation and Trend Overview
5.2 Biopharmaceuticals Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOPHARMACEUTICALS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biopharmaceuticals in EMEA by Major Players
6.2 Revenue of Biopharmaceuticals in EMEA by Major Players
6.3 Basic Information of Biopharmaceuticals by Major Players
6.3.1 Headquarters Location and Established Time of Biopharmaceuticals Major Players
6.3.2 Employees and Revenue Level of Biopharmaceuticals Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOPHARMACEUTICALS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biopharmaceuticals Product
7.1.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biopharmaceuticals Product
7.2.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biopharmaceuticals Product
7.3.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biopharmaceuticals Product
7.4.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biopharmaceuticals Product
7.5.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biopharmaceuticals Product
7.6.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biopharmaceuticals Product
7.7.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biopharmaceuticals Product
7.8.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biopharmaceuticals Product
7.9.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biopharmaceuticals Product
7.10.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Merck
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOPHARMACEUTICALS
8.1 Industry Chain of Biopharmaceuticals
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOPHARMACEUTICALS
9.1 Cost Structure Analysis of Biopharmaceuticals
9.2 Raw Materials Cost Analysis of Biopharmaceuticals
9.3 Labor Cost Analysis of Biopharmaceuticals
9.4 Manufacturing Expenses Analysis of Biopharmaceuticals
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOPHARMACEUTICALS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
